Evan CP - Search Results

1

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.

Francini E, Yip S, Ahmed S, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ. Francini E, et al. Among authors: evan cp. Clin Genitourin Cancer. 2018 Apr;16(2):130-134. doi: 10.1016/j.clgc.2017.12.012. Epub 2017 Dec 27. Clin Genitourin Cancer. 2018. PMID: 29331381 Free PMC article. Clinical Trial.

2

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.

Muralidhar V, Regan MM, Werner L, Nakabayashi M, Evan CP, Bellmunt J, Choueiri TK, Elfiky AA, Harshman LC, McKay RR, Pomerantz MM, Sweeney CJ, Taplin ME, Kantoff PW, Nguyen PL. Muralidhar V, et al. Among authors: evan cp. Clin Genitourin Cancer. 2016 Aug;14(4):e299-305. doi: 10.1016/j.clgc.2015.12.008. Epub 2015 Dec 17. Clin Genitourin Cancer. 2016. PMID: 26778006 Clinical Trial.

3

Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.

Francini E, Gray KP, Shaw GK, Evan CP, Hamid AA, Perry CE, Kantoff PW, Taplin ME, Sweeney CJ. Francini E, et al. Among authors: evan cp. Prostate Cancer Prostatic Dis. 2019 Sep;22(3):420-427. doi: 10.1038/s41391-018-0121-2. Epub 2019 Jan 14. Prostate Cancer Prostatic Dis. 2019. PMID: 30643173 Free PMC article.

4

Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival.

Sharma J, Gray KP, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ. Sharma J, et al. Prostate. 2014 Feb;74(3):225-34. doi: 10.1002/pros.22744. Epub 2013 Oct 16. Prostate. 2014. PMID: 24132762

5

Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival.

Sharma J, Gray KP, Harshman LC, Evan C, Nakabayashi M, Fichorova R, Rider J, Mucci L, Kantoff PW, Sweeney CJ. Sharma J, et al. Prostate. 2014 Jun;74(8):820-8. doi: 10.1002/pros.22788. Epub 2014 Mar 26. Prostate. 2014. PMID: 24668612

6

Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less.

Parekh A, Chen MH, Graham P, Mahal BA, Hirsch AE, Nakabayashi M, Evan C, Kantoff PW, Martin NE, Nguyen PL. Parekh A, et al. Clin Genitourin Cancer. 2015 Feb;13(1):e1-6. doi: 10.1016/j.clgc.2014.06.016. Epub 2014 Jun 27. Clin Genitourin Cancer. 2015. PMID: 25103271

7

Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases.

McGregor B, Zhang L, Gray KP, Shaw G, Evan C, Francini E, Sweeney C. McGregor B, et al. Prostate Cancer Prostatic Dis. 2021 Jun;24(2):341-348. doi: 10.1038/s41391-020-00280-6. Epub 2020 Sep 3. Prostate Cancer Prostatic Dis. 2021. PMID: 32884090 Clinical Trial.

8

Development of an integrated prostate cancer research information system.

Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J. Oh WK, et al. Clin Genitourin Cancer. 2006 Jun;5(1):61-6. doi: 10.3816/CGC.2006.n.019. Clin Genitourin Cancer. 2006. PMID: 16859581

9

Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease.

Tsao CK, Gray KP, Nakabayashi M, Evan C, Kantoff PW, Huang J, Galsky MD, Pomerantz M, Oh WK. Tsao CK, et al. J Urol. 2015 Jul;194(1):91-7. doi: 10.1016/j.juro.2015.01.078. Epub 2015 Jan 24. J Urol. 2015. PMID: 25623747

10

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.

Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, Loda M, Corcoran NM, Van Allen EM, Choudhury AD, Sweeney CJ. Hamid AA, et al. Eur Urol. 2019 Jul;76(1):89-97. doi: 10.1016/j.eururo.2018.11.045. Epub 2018 Dec 12. Eur Urol. 2019. PMID: 30553611

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13 results

Search Page